現代中藥集團(01643.HK)預計年度淨溢利800萬至1200萬元
格隆匯3月6日丨現代中藥集團(01643.HK)公告,集團預計截至2024年12月31日止年度錄得金額介於人民幣8.0百萬元至人民幣12.0百萬元的淨溢利,而截至2023年12月31日止年度則錄得約人民幣48.8百萬元的淨溢利。
淨溢利有所下降乃主要歸因於1)於2024年2月至5月期間因製劑車間進行修繕工程引致的暫時停產及受國家新政策影響以及活躍客戶數量下降導致收益減少;及2)拆除製劑車間導致的物業、廠房及設備處置損失。儘管如此,董事會預計集團整體營運及現金流量不會受到重大不利影響。於本公告日期,集團擁有充足的手頭現金應付其現時業務所需。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.